A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091

Status:
Recruiting

Trial end date:
2021-12-26

Target enrollment:

Participant gender:

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-109 in healthy male subjects.

Phase 1

Addpharma Inc.

Rivaroxaban